KONEXBiotech & Pharma270210

SR biotek

₩9,700▼ 0.92%2026-11-18 close
Market Cap
₩16.6B
Turnover
₩1,324,270
Volume
143 shares
Shares out.
1.7M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Own brands reshape the P&L

After shifting toward its own brand, SR biotek posted profits in both 2024 and 2025, but that record still covers only two years.

  1. 1

    Revenue for 2025 was KRW 37.4 billion and operating profit was KRW 2.59 billion, with both metrics rising roughly 27%.

  2. 2

    Operating profit has been positive since 2024, following an operating loss of KRW 1.33 billion in 2023, which marks a turnaround pattern.

  3. 3

    The revenue mix is shifting from contract manufacturing toward its own E-Dinell brand and the Altum peptide platform.

  4. 4

    Overseas sales are reported at more than 95% of revenue, which leaves the company highly exposed to exchange rates and foreign demand.

  5. 5

    The largest shareholder holds 58.04% and the free float is 41.96%, while the share price fell 50.04% over six months.

02

Business structure

SR biotek is a cosmetics manufacturer founded in 2007 that specializes in functional cosmetics and is listed on the KONEX market. Its core technology is Altum peptide, a new material that combines microneedles with peptides, which was developed in 2020 and launched in 2021.

Since 2023 the company has reduced OEM/ODM contract production and pushed its own brand, E-Dinell, into the professional channel. Its earnings commentary links the margin improvement to the growth of own-brand sales.

Company profile information on a recruitment platform puts overseas sales at more than 95% of revenue, with partners spread across more than 100 countries including the United States, France, the United Kingdom, the Middle East and South America.

The company states that more than KRW 3 billion in research funding has been invested over 15 years in the Altum patent technology. It has registered patents and trademarks in Europe and the United States to broaden its overseas base. R&D spending in 2025 was KRW 1.09 billion, equal to 2.92% of revenue.

Within the cosmetics sector, share price performance diverges by company depending on overseas sales mix, product competitiveness and order and earnings outlooks.

03

Recent trends

Revenue for 2025 was KRW 37.4 billion, up 27.10% from the prior year. Operating profit rose 27.35% to KRW 2.59 billion, and net profit rose 98.44% to KRW 3.27 billion. The operating margin for 2025 was 6.92% and the net margin was 8.73%.

Revenue for 2024 jumped 260.22% to KRW 29.4 billion, and operating profit of KRW 2.03 billion marked a return to profit after the 2023 operating loss of KRW 1.33 billion. Operating cash flow from ordinary activities turned positive at KRW 1.29 billion in 2025, compared with a negative KRW 283 million in 2024.

Total assets at the end of 2025 stood at KRW 9.67 billion, and the debt ratio fell to 75.46% from 194.03% in 2024. The share price moved between a 52-week high of KRW 33,950 and a low of KRW 8,010, and the six-month return as of the October 2, 2026 snapshot was -50.04%.

A July 8, 2026 market report cited the company among stocks that rose more than KRW 1,000 on a day when cosmetics shares turned weak. Press reports said the share price rose 701.14% over 2024.

04

Outlook

The key question for the outlook is whether the earnings improvement seen in 2025 carries into 2026.

The company cites the expansion of its own brand E-Dinell in the professional channel and the competitiveness of its microneedle products as drivers of the profit recovery, so whether these two factors show up in quarterly sales is the central issue.

The Altum peptide platform is described as extendable to a range of active ingredients, and overseas trademark and patent registrations have been completed. The capital structure, which moved out of capital impairment in 2024, showed a debt ratio of 75.46% at the end of 2025, and the debt dependence ratio was 14.74%.

With the largest shareholder holding 58.04% and a free float of 41.96%, trading liquidity is relatively limited. The share price, as of the October 2, 2026 snapshot, sits well below the 52-week high of KRW 33,950.

The next checkpoints are cumulative results through the third quarter of 2026 and any change in the overseas sales share. The medium-term direction depends on whether participation in overseas trade shows and expansion of global partners convert into revenue.

05

Bull factors

Own-brand shift and margin recovery

Since 2023 the company has cut back on OEM/ODM production and pushed its own E-Dinell brand into the professional channel. Its 2025 earnings commentary attributes higher sales and operating profit to that channel entry and to stronger microneedle product competitiveness.

If the 6.92% operating margin holds, the reading that a larger own-brand mix is changing the profit structure gains support.

Cash flow and balance sheet improving together

Operating cash flow from ordinary activities turned positive at KRW 1.29 billion in 2025 after a negative figure in 2024. Over the same period the debt ratio fell from 194.03% to 75.46%, and the company moved out of capital impairment in 2024. Whether profits keep converting into cash is the evidence on which the bullish case rests.

Technology assets and overseas registrations

The Altum peptide platform is presented as a base that can be extended to a range of active ingredients. Overseas trademark and patent registrations have been completed, and a European patent was registered in 2023.

R&D spending in 2025 was KRW 1.09 billion, or 2.92% of revenue, and how these technology assets connect to overseas sales growth is the medium-term point to watch.

06

Bear factors

A short profit record and past capital impairment

Revenue in 2023 was KRW 8.17 billion with an operating loss of KRW 1.33 billion, and total equity at the end of 2023 was negative KRW 1.35 billion. Profitability covers only two years, 2024 and 2025.

Because profits have grown from a small equity base, the reported ROE of 84.92% looks high, and the durability of earnings has yet to be tested over a longer period.

Reliance on overseas sales and sector dispersion

Overseas sales are reported at more than 95% of revenue, so earnings are sensitive to exchange rates, consumer demand in export markets and local regulatory changes. Within the cosmetics sector, share performance diverges sharply by company depending on overseas mix, product competitiveness and order outlooks.

The stock was cited as a gainer on a July 2026 day when cosmetics shares turned weak, but its moves can diverge from the sector as a whole.

Thin free float and large share price swings

Specially related parties, led by the largest shareholder, hold 58.04%, leaving a free float of 41.96%. The share price ranged between a 52-week high of KRW 33,950 and a low of KRW 8,010, and the six-month return was -50.04%. Combined with the KONEX listing and limited liquidity, price swings can be wide.

07

Risk factors

Macro

With overseas sales making up most of revenue, the direction of the won against major currencies and consumer demand in export markets directly affect sales and earnings. A sharp move in exchange rates could affect both overseas order prices and margins. A pullback in global cosmetics demand could also delay orders from partners.

Regulatory and licensing

Cosmetics launch timing depends on national sanitary permits and functional certification regimes. The company received Chinese CFDA approval for four functional cosmetics in 2020, and changes in market-specific permit requirements affect the pace of overseas expansion. Delays in new-country entry or product registration could also slow partner expansion.

Ownership and liquidity

With the largest shareholder holding 58.04%, the number of shares trading in the market is limited. As a KONEX-listed company, price discovery can weaken when institutional and foreign participation is restricted. In this structure, a small number of large trades can move the share price significantly.

08

Overall view

SR biotek reported that revenue, operating profit and net profit for 2025 all rose from the prior year on an aggregated filings basis. Profits in both 2024 and 2025 and the positive operating cash flow from ordinary activities in 2025 are evidence of improving financial strength.

However, the losses and capital impairment through 2023 mean the record of sustained earnings is still short. A high overseas sales share exposes the company to exchange rates and export-market demand.

The share price fell close to 50% over six months, and the low free float tied to the largest shareholder's 58.04% stake can amplify trading volatility.

The picture is one in which bullish factors, namely earnings improvement and the own-brand strategy, coexist with bearish factors, namely a short profit history, overseas dependence and thin liquidity.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. alphasquare.co.kr
  2. comp.wisereport.co.kr
  3. comp.wisereport.co.kr
  4. comp.fnguide.com
  5. jobkorea.co.kr
  6. saramin.co.kr
  7. prestocknews.com
  8. thevc.kr
  9. wanted.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis